World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
115
Citations
61383
World Ranking
389
National Ranking
35

Medicine

D-Index
115
Citations
61598
World Ranking
4467
National Ranking
440

Andrew J. Pollard publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Andrew J. Pollard sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 823 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Andrew J. Pollard D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Andrew J. Pollard sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 115 D-Index — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Andrew J. Pollard is affiliated with the University of Oxford in the United Kingdom. Their research primarily spans the field of Medicine, with a significant focus on Infectious Diseases, Epidemiology, Health, Immunology, and Food Science as subfields of study.

Pollard's work covers various main topics including:

  • SARS-CoV-2 and COVID-19 Research
  • Respiratory viral infections research
  • Viral gastroenteritis research and epidemiology
  • Vaccine Coverage and Hesitancy
  • COVID-19 Clinical Research Studies
  • Pneumonia and Respiratory Infections
  • Salmonella and Campylobacter epidemiology

Recent papers authored or co-authored by Pollard include:

  • "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK" (2020), published in The Lancet
  • "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial" (2020), published in The Lancet
  • "A guide to vaccinology: from basic principles to new developments" (2020), published in Nature Reviews. Immunology
  • "Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant" (2021), published in New England Journal of Medicine
  • "Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment" (2021), published in The Lancet

Pollard frequently collaborates with several co-authors, including:

  • Federico Martinón-Torres
  • Teresa Lambe
  • Peter Openshaw
  • Harish Nair
  • Sagida Bibi

Their research has been published in numerous venues, with recurring publications in:

  • The Journal of Infectious Diseases
  • bioRxiv (Cold Spring Harbor Laboratory)
  • The Lancet
  • Vaccine
  • SSRN Electronic Journal

Best Publications

  • Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

    M Voysey;Clemens Sac.;S A Madhi;L Y Weckx

  • Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

    P M Folegatti;K J Ewer;P K Aley;B Angus

  • A guide to vaccinology: from basic principles to new developments

    Andrew J. Pollard;Else M. Bijker

  • Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

    M Voysey;S A Costa Clemens;S A Madhi;L Y Weckx

  • Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment.

    Olivier J Wouters;Kenneth C Shadlen;Maximilian Salcher-Konrad;Andrew J Pollard

  • Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

    Unknown

  • Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.

    S. A. Madhi;V. Baillie;C. L. Cutland;M. Voysey

  • Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

    M N Ramasamy;A M Minassian;K J Ewer;A L Flaxman

  • Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.

    Shuo Feng;Daniel J. Phillips;Thomas White;Homesh Sayal

  • Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.

    D Zhou;W Dejnirattisai;P Supasa;C Liu

  • Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

    Pedro M Folegatti;Katie J Ewer;Parvinder K Aley;Brian Angus

  • COVID-19 Vaccine Hesitancy in the UK: The Oxford Coronavirus Explanations, Attitudes, and Narratives Survey (OCEANS) II.

    Daniel Freeman;Daniel Freeman;Bao S. Loe;Andrew Chadwick;Cristian Vaccari

  • Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

    Unknown

  • Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.

    C Liu;H M Ginn;W Dejnirattisai;P Supasa

  • What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.

    Susanne H Hodgson;Kushal Mansatta;Garry Mallett;Victoria Harris

  • Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

    Katherine R W Emary;Tanya Golubchik;Parvinder K Aley;Cristina V Ariani

  • T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

    K J Ewer;Barrett;S Belij-Rammerstorfer;H Sharpe

  • Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.

    Andrew J. Pollard;Kirsten P. Perrett;Peter C. Beverley

  • Antibody evasion by the P.1 strain of SARS-CoV-2.

    W Dejnirattisai;D Zhou;P Supasa;C Liu

  • Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.

    P Supasa;D Zhou;W Dejnirattisai;C Liu

  • A CD8 + T cell transcription signature predicts prognosis in autoimmune disease

    Eoin F McKinney;Paul A Lyons;Edward J Carr;Jane L Hollis

  • Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine (preprint)

    Voysey, Merryn, Costa Clemens, Sue Ann, Madhi, Shabir A.;Weckx, Lily Yin, Folegatti, Pedro M.;Parvinder K. Aley;Angus, Brian John, Baillie, Vicky, Barnabas, Shaun L.

Frequent Co-Authors

Matthew D. Snape
Matthew D. Snape University of Oxford
Adam Finn
Adam Finn University of Bristol
Paul T. Heath
Paul T. Heath St George's, University of London
Saul N. Faust
Saul N. Faust University Hospital Southampton NHS Foundation Trust
Daniel T. O'Connor
Daniel T. O'Connor University of California, San Diego
Teresa Lambe
Teresa Lambe University of Oxford
Michael Levin
Michael Levin Tufts University
Gordon Dougan
Gordon Dougan University of Cambridge
Sarah C. Gilbert
Sarah C. Gilbert University of Oxford
Paul Klenerman
Paul Klenerman University of Oxford

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those studying immunology in the USA, expanding into healthcare roles can open diverse career opportunities. Many professionals consider advancing their education by exploring specialized online programs, such as the top psychiatric mental health nurse practitioner programs online. These programs offer flexibility and strong clinical placement rates, ideal for working students aiming to enhance their credentials in mental health settings.

Cost is also a significant factor when pursuing further education. Students should explore the cheapest pmhnp programs to find quality education that fits their budget without compromising on clinical experience and certification readiness.

Understanding financial outcomes post-graduation is crucial. The dnp salary information highlights how salaries can vary regionally, helping graduates make informed decisions on where to work or specialize. This data is especially useful for those who hold a Doctor of Nursing Practice degree and are assessing return on investment.

Additionally, transitions within nursing specialties, like moving from family nurse practitioner roles, are common. Guidance on acute care certification for fnp enables nurses to broaden their expertise and take on acute care responsibilities—skills that complement immunology knowledge in clinical practice.

Best Scientists Citing Andrew J. Pollard

Trending Scientists

Recently Published Articles